FDA Questions Accelerated Approval For AstraZeneca’s Olaparib In Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs Advisory Committee will consider whether the first-in-class PARP inhibitor should come to market on the basis of Phase II data in a subgroup of patients or await results from an ongoing confirmatory study. Agency cites “uncertainties” about validity and magnitude of effect seen in the Phase II trial.
You may also be interested in...
AstraZeneca Takes Impairment Charge After Olaparib, TC-5214 Setbacks
Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.
US FDA’s Non-Cancer Accelerated Approval Drugs Get Their Own Public Databases
Accelerated Approval Program web page links to searchable databases for accelerated approvals of infectious disease products, vaccines, and other nonmalignant indications. New databases, which include products that converted to regular approval or were withdrawn, are modeled after Oncology Center of Excellence’s cancer drug databases that debuted in 2021.
GSK’s Blenrep: 15 Days From Confirmatory Trial Failure To Withdrawal Announcement
The first BCMA-targeting agent to gain approval in myeloma never became the blockbuster for which GSK had hoped, but Blenrep appears to have set a new standard for speed of voluntary withdrawal of an accelerated approval drug after a confirmatory trial failure.